Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Chronic Myelomonocytic Leukemia

English

Dr. Konopleva's research focus is on studying novel agents in acute myeloid and lymphocytic leukemias, focusing on BCL-2 targeting and agents targeting leukemic microenvironment and metabolism. Dr. Konopleva has extended her research to include clinical translational investigations and has developed clinical trials based on laboratory discoveries. These include BCL-2 inhibitor venetoclax, inhibitor of oxidative phosphorylation, CXCR4 inhibitors, AKT and mTOR inhibitors and hypoxia-activated prodrugs.